Kura Oncology (KURA)
NASDAQ:KURA
KURA Stock Chart & Stats
$8.07
-$0.35(-4.35%)
At close: 4:00 PM EST
$8.07
-$0.35(-4.35%)
Day’s Range― - ―
52-Week Range$5.41 - $12.49
Previous CloseN/A
Volume631.17K
Average Volume (3M)1.52M
Market Cap
$734.90M
Enterprise Value$626.14M
Total Cash (Recent Filing)$667.24M
Total Debt (Recent Filing)$20.46M
Price to Earnings (P/E)―
Beta1.37
Next Earnings
Apr 30, 2026EPS Estimate
-0.81Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.92
Shares Outstanding88,329,760
10 Day Avg. Volume1,369,800
30 Day Avg. Volume1,516,650
Financial Highlights & Ratios
PEG Ratio-0.06
Price to Book (P/B)5.23
Price to Sales (P/S)13.50
P/FCF Ratio-12.89
Enterprise Value/Market Cap0.85
Enterprise Value/Revenue9.28
Enterprise Value/Gross Profit9.81
Enterprise Value/Ebitda-2.16
Forecast
1Y Price Target
$27.75Price Target Upside243.87% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering10
EPS Forecast (FY)-3.52
Revenue Forecast (FY)$118.28M
Bulls Say, Bears Say
Bulls Say
Clinical Data CatalystsPlanned clinical data readouts and combination trial updates for ziftomenib and darlifarnib offer multiple opportunities to validate efficacy in additional indications and expand the addressable market.
Commercial Uptake And Payer CoverageInitial commercial sales combined with broad early payer coverage for Komzifti indicate solid launch momentum and suggest sustained physician and patient demand.
Financial Resources And Patent ProtectionA strong cash balance supplemented by anticipated collaboration milestone payments should fund pivotal development through initial topline results, while Orange Book patent listings support longer-term U.S. market exclusivity for Komzifti.
Bears Say
Competitive PressureManagement's expectation that the market can support multiple competitors, together with signs of increasing competitor share, points to growing competitive pressure that could limit Komzifti adoption.
Earnings Performance And DilutionReported quarterly and full‑year results that missed analyst expectations, coupled with increases in share count, could pressure earnings per share metrics and investor sentiment.
Payer Access RestrictionsStep-edit requirements being implemented by several large commercial plans based on pricing analysis may restrict patient access to Komzifti while competitors face fewer such limitations.
Kura Oncology News
KURA FAQ
What was Kura Oncology’s price range in the past 12 months?
Kura Oncology lowest stock price was $5.41 and its highest was $12.49 in the past 12 months.
What is Kura Oncology’s market cap?
Kura Oncology’s market cap is $734.90M.
When is Kura Oncology’s upcoming earnings report date?
Kura Oncology’s upcoming earnings report date is Apr 30, 2026 which is in 35 days.
How were Kura Oncology’s earnings last quarter?
Kura Oncology released its earnings results on Mar 05, 2026. The company reported -$0.92 earnings per share for the quarter, missing the consensus estimate of -$0.639 by -$0.281.
Is Kura Oncology overvalued?
According to Wall Street analysts Kura Oncology’s price is currently Undervalued.
Does Kura Oncology pay dividends?
Kura Oncology does not currently pay dividends.
What is Kura Oncology’s EPS estimate?
Kura Oncology’s EPS estimate is -0.81.
How many shares outstanding does Kura Oncology have?
Kura Oncology has 88,329,760 shares outstanding.
What happened to Kura Oncology’s price movement after its last earnings report?
Kura Oncology reported an EPS of -$0.92 in its last earnings report, missing expectations of -$0.639. Following the earnings report the stock price went down -0.468%.
Which hedge fund is a major shareholder of Kura Oncology?
Currently, no hedge funds are holding shares in KURA
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Kura Oncology Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$27.75 (243.87% Upside)
$27.75 (243.87% Upside)
Blogger Sentiment
Bullish
KURA Sentiment 100%
Sector Average ―
Sector Average ―
Hedge Fund Trend
Increased
By 456.5K Shares
Last Quarter.
Last Quarter.
Insider Transactions
Sold Shares
Worth $305.1K over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Negative
Last 7 Days >0.1%
Last 30 Days ▼ 2.1%
Last 30 Days ▼ 2.1%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Positive
20 days / 200 days
Momentum
5.49%
12-Months-Change
Fundamentals
Return on Equity
-102.59%
Trailing 12-Months
Asset Growth
-29.05%
Trailing 12-Months
Company Description
Kura Oncology
Kura Oncology, Inc., a clinical-stage biopharmaceutical company, develops medicines for the treatment of cancer in the United States. The company's pipeline consists of small molecule product candidates that target cancer. Its lead product candidates are ziftomenib, a small molecule inhibitor of the menin-Lysine K-specific Methyltransferase 2A protein-protein interaction for the treatment of genetically defined subsets of acute leukemias, including acute myeloid leukemia and acute lymphoblastic leukemia; and tipifarnib, an orally bioavailable inhibitor of farnesyl transferase that is in Phase II clinical trials for the treatment of solid tumors and hematologic indications. The company has a clinical collaboration with Novartis to evaluate the combination of tipifarnib and alpelisib in patients with head and neck squamous cell carcinoma whose tumors have HRAS overexpression or PIK3CA mutation and/or amplification. Kura Oncology, Inc. was founded in 2014 and is headquartered in San Diego, California.
KURA Earnings Call
Q4 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call presents a predominantly positive commercial and clinical story: FDA approval, immediate product shipments, rapid payer coverage (~84% of private payers within 90 days), beneficial payer step edits, patent protection to 2044, robust sales force deployment, and multiple near‑term clinical catalysts across AML and the FTI program. Financially, the company is investing heavily in commercialization and development, which widened operating losses and reduced collaboration revenue year-over-year; cash remains substantial (~$667M) with anticipated milestone support through top-line Phase 3 readout in 2028. Overall, strengths in launch execution, access, patent protection, and a data-rich development plan outweigh near‑term financial pressures and uncertainties around duration of therapy and reliance on milestone timing.View all KURA earnings summariesKURA Stock 12 Month Forecast
Average Price Target
$27.75
▲(243.87% Upside)
Technical Analysis
Oruka Therapeutics
―
Phathom Pharmaceuticals
―
Keros Therapeutics
―
Tyra Bioscience
―
Septerna, Inc.
―
Ownership Overview
2.47% Insiders
10.76% Mutual Funds
41.30% Other Institutional Investors
29.52% Public Companies and
Individual Investors